OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

Study Overview
=================
Brief Summary
-----------------
OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent. In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.

Official Title
-----------------
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)

Conditions
-----------------
Diabetes Mellitus, Non-Insulin-Dependent

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent Able to read and send SMS (if SMS applicable) Exclusion Criteria: Type 1 diabetes Pregnancy diabetes Hospitalization at the moment of enrollment in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with diabetes type 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1 | To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure, expressed as the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c1 | after 12 months of follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of patient care improvement, in particular the control of diabetes, lipids and blood pressure | To investigate whether the use of benchmarking could improve quality of patient care, in particular the control of diabetes, lipids and blood pressure | after 12 months of follow-up versus baseline | 
| Markers of preventive screening | To follow up evolution markers of preventive screening; retinopathy, neuropathy, dietary counseling, smoking habits, BMI, waist circumference, physical activity | after 12 months of follow-up versus baseline | 
| The LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines | To investigate the LDL cholesterol parameter of the primary and secondary objectives according to ATP III guidelines | after 12 months of follow-up versus baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benchmarking could improve quality of patient care, ESC and ATP III Guidelines